Aravive Inc

Aravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aravive Biologics is a clinical-stage biotechnology company that focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies.

HOUSTON, March  24, 2020  (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored Phase 1/2 clinical trial of the company’s GAS6/AXL inhibitor AVB-500 in combination with PD-L1 inhibitor avelumab in patients with advanced urothelial carcinoma (UC). The study is being led by Abhishek Tripathi, M.D., Assistant Professor of Medicine, Section of hematology/oncology at the University of Oklahoma Stephenson Cancer Center.

Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)

Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline

Aravive Announces Management Changes

HOUSTON, Dec.  20, 2019  (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling patients in the Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically IgA Nephropathy (IgAN) (NCT04042623).

Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis

Investors need to pay close attention to Aravive (ARAV) stock based on the movements in the options market lately.

Implied Volatility Surging for Aravive (ARAV) Stock Options

HOUSTON, Nov.  27, 2019  (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced the pricing of its previously announced underwritten public offering of 3,333,334 shares of its common stock at a public offering price of $7.50 per share.  Aravive expects to receive gross proceeds of approximately $25 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Aravive.

Aravive Announces Pricing of Public Offering of Common Stock

HOUSTON, Nov.  26, 2019  (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that it has commenced an underwritten public offering of the sale of its shares of common stock. In connection with this offering, Aravive intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. All of the shares are being offered by Aravive. Aravive currently intends to use the net proceeds from this offering primarily for research, development and manufacturing of product candidates, and for other general corporate purposes including, to acquire, license or invest in complementary businesses, technologies, product candidates or other intellectual property.

Aravive Announces Proposed Public Offering of Common Stock

Aravive Inc. (NASDAQ: ARAV) shares skyrocketed on Wednesday after the firm announced early-stage data for its ovarian cancer treatment.

A Big Step Forward in the Fight Against Ovarian Cancer

Aravive stock doubled in value Wednesday after the biotech company delivered bullish test results for a high-dose ovarian cancer treatment vs. a lower dose of the same experimental medicine.

Here's Why This Tiny Biotech Stock Doubled In Value Overnight

Shares of Aravive ARAV, +3.40% are up 270% in premarket trading Wednesday after the Houston-based biotech reported positive data from an early-stage clinical trial.

Aravive shares jump on ovarian cancer data

Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity

News for Aravive Inc Stock (ARAV)